Dr. Anuj Goenka, MD
Claim this profileLenox Hill Brain Tumor Center
Studies Glioblastoma
Studies Brain Cancer
8 reported clinical trials
11 drugs studied
Affiliated Hospitals
Clinical Trials Anuj Goenka, MD is currently running
CAPTEM
for Glioblastoma
The purpose of this study is to evaluate the safety and efficacy of administering the medication capecitabine along with temozolomide when you start your monthly regimen of oral temozolomide for the treatment of your newly diagnosed glioblastoma multiforme (GBM). Capecitabine is an oral chemotherapy that is given to patients with other types of cancer. The study will evaluate whether the dosage of 1500 mg/m2 of capecitabine is tolerable after radiation, when taken along with temozolomide. It will also try to determine if the medication capecitabine helps patients respond to treatment for a longer period of time compared to just temozolomide alone, which is the standard of care.
Recruiting3 awards Phase 1 & 2
Stereotactic Radiosurgery vs Whole-Brain Radiotherapy
for Brain Metastasis from Lung Cancer
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiation to the entire brain including the normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT) decreases the amount of radiation that is delivered to the hippocampus which is a brain structure that is important for memory. The drug, memantine, is also often given with whole brain radiotherapy because it may decrease the risk of side effects related to thinking and memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking compared to standard of care HA-WBRT plus memantine.
Recruiting2 awards Phase 315 criteria
More about Anuj Goenka, MD
Clinical Trial Related6 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Anuj Goenka, MD has experience with
- Stereotactic Radiosurgery
- Cetuximab
- Whole-Brain Radiotherapy
- Capecitabine
- Temozolomide
- Cetuximab (Erbitux)
Breakdown of trials Anuj Goenka, MD has run
Glioblastoma
Brain Cancer
Cancer
Brain Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Anuj Goenka, MD specialize in?
Anuj Goenka, MD focuses on Glioblastoma and Brain Cancer. In particular, much of their work with Glioblastoma has involved EGFR positive patients, or patients who are undergoing treatment.
Is Anuj Goenka, MD currently recruiting for clinical trials?
Yes, Anuj Goenka, MD is currently recruiting for 4 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Anuj Goenka, MD has studied deeply?
Yes, Anuj Goenka, MD has studied treatments such as Stereotactic Radiosurgery, Cetuximab, Whole-Brain Radiotherapy.
What is the best way to schedule an appointment with Anuj Goenka, MD?
Apply for one of the trials that Anuj Goenka, MD is conducting.
What is the office address of Anuj Goenka, MD?
The office of Anuj Goenka, MD is located at: Lenox Hill Brain Tumor Center, New York, New York 10075 United States. This is the address for their practice at the Lenox Hill Brain Tumor Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.